starting dose of glp 1 Customized Compounded GLP-1 Weight Loss Plans Dosage of GLP-1 analogues |

Michelle Gourdine, Chief Medical Officer at CVS Caremark, explains how combining medication with health coaching and lifestyle support can help patients achieve more sustainable outcomes

To address this growing global challenge, the World Health Organization (WHO) has developed a guideline on the use of glucagon-like peptide-1 (GLP-1) based therapies, including GLP-1 receptor agonists and GLP-1/GIP dual agonists, for adults living with obesity.Join us at the virtual launch event in a webinar hosted by WHO in collaboration with the Journal of the American Medical Association (JAMA) on 1 December 2025 at 16:00 CET

One shows a pharmacy trend line, like GLP-1 utilization climbing faster than anyone budgeted for, with leadership asking if next years plan can absorb it.

We use a dynamic microsimulation to estimate value-based prices that account for the health benefits, medical savings and productivity gains these treatments provide

Among people with pre-existing SUDs, initiation of GLP-1 receptor agonists was associated with reduced risk of SUD related emergency department visits (0.69 (0.61 to 0.78), NRD 8.92 (11.59 to 6.25)), SUD related hospital admissions (0.74 (0.65 to 0.85), NRD 6.23 (8.73 to 3.74)), and SUD related mortality (0.50 (0.32 to 0.79), NRD 1.52 (2.32 to 0.72)), and drug overdose (0.61 (0.42 to 0.88), NRD 1.49 (2.43 to 0.55)) and suicidal ideation or attempt (0.75 (0.67 to 0.83), NRD 9.95 (13.14 to 6.77))

Start with the gut